Menu

Stephen Rusckowski

Dec 15, 2016

Quest Diagnostics has appointed Stephen Rusckowski as the chairman of its board of directors. Rusckowski succeeds Daniel Stanzione, who will be staying on as lead independent director. Rusckowski joined Quest in 2012 and continues to serve as president and CEO.

More Like This

Transplant Genomics (TGI) and Viracor Eurofins announced that they have formed the Eurofins Transplant medical and scientific advisory board, which will be convened by Eurofins TGI's VP of Medical Affairs John Holman. The board will include Roz Mannon, University of Nebraska; Michael Abecassis, University of Arizona; Fuad Shihab, University of Utah; Win Williams, Massachusetts General Hospital; Anil Chandraker, Brigham and Women's Hospital; Allan Kirk, Duke University; Jonathan Bromberg, University of Maryland; Robert Fairchild, Cleveland Clinic; and Matt Cooper, Georgetown University.

The board consists of people with diverse expertise and experience in transplantation technology development and clinical studies, and will be tasked with providing independent advice on unmet clinical needs in transplantation to guide the evolution of TGI and Viracor's current and future products that expand the indications for its TruGraf and Trac product lines through clinical studies. The board will also provide advice on R&D or acquisition of additional disruptive technologies for the Eurofins transplant portfolio.

Jun 04, 2020

NeoGenomics: Rachel Stahler

NeoGenomics announced Rachel Stahler would join the company's board of directors, effective immediately. She will serve on the board's audit committee. Stahler was recently named the chief information officer for Merck's intended women's health and biosimilars spinoff Organon & Co. Previously, she was the CIO at pharmaceuticals firm Allergan, Syneos Health, and Optimer Pharmaceuticals.

Jun 02, 2020

Chembio Diagnostics: Chuck Caso

Chembio Diagnostics has appointed Chuck Caso as its vice president of sales and marketing for North America with responsibility for direct and channel sales efforts throughout the region.

Caso brings more than 20 years of diagnostics industry experience to his new role. He has served in various executive sales and marketing roles at Meridian Biosciences, Quest Diagnostics, and Danaher.

May 29, 2020

OraSure Technologies: Lelio Marmora

OraSure Technologies has appointed Lelio Marmora as a member of the company's board of directors, effective June 1. Marmora previously served as executive director of Unitaid and also held senior positions at the Global Fund to Fight AIDS, TB and, Malaria.

May 29, 2020

Castle Biosciences: Federico Monzon

In a filing with the US Securities and Exchange Commission, Castle Biosciences said that Chief Medical Officer Federico Monzon notified the company on May 21 that he plans to resign, effective May 31. In November 2019, the firm had disclosed Monzon's intention to resign on or about April 1, 2020, but the move was subsequently delayed.

May 28, 2020

Gradientech: Gisela Sitbon, Rolf Ehrnström, Simon Turner

Gradientech has added three new board members: Gisela Sitbon, Rolf Ehrnström, and Simon Turner. Sitbon boasts more than 25 years of senior level life science experience and will be the new chair of the board at the Uppsala, Sweden-based developer of rapid phenotypic antibiotic suceptibility testing. Ehrnström, meanwhile, has experience in research and development at companies such as Amersham Pharmacia Biotech, Dako, and Gyros, while Turner is an investment analyst.

May 28, 2020

First Light Diagnostics: Andrew Wilsack

First Light Diagnostics has appointed Andrew Wilsack its CFO. He has more than 25 years of experience in the life science industry, including most recently as a financial consultant at Danforth Advisors. Previously, he was vice president of FPA at Masimo and CFO at Argose.

May 28, 2020

Myriad Genetics: John Henderson, Daniel Spiegelman

Myriad Genetics said that John Henderson will retire from its board of directors at its annual meeting in December. Henderson chaired the board from April 2005 through March 2020, at which point Louise Phanstiel was elected to serve as chair. The company has also elected to its board of directors Daniel Spiegelman, who was most recently executive VP and CFO of BioMarin Pharmaceuticals. After retiring from that role, Spiegelman has been serving on the board of Tizona Therapeutics, as well on the boards of several biotech firms.

May 27, 2020

AXIM Biotechnologies: Sergei Svarovsky

AXIM Biotechnologies has appointed Sergei Svarovsky as the CSO of subsidiary Sapphire Biotech. Svarovsky previously served as a research fellow at the National Institute of Health's National Cancer Institute. AXIM noted that Svarovsky has experience with cancer drug design medical diagnostics develompent, including developing a wide range of biological assays for existing and novel platforms for many well-known biotech firms.

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry as its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

May 26, 2020

Proteomedix: Maurizo Ballerini, Helene Peyro Saint-Paul

Swiss cancer diagnostics company Proteomedix has appointed Maurizo Ballerini as vice president of market development for Europe, the Middle East, and Africa, and Helene Peyro Saint-Paul as medical advisor. Both appointments are effective June 1. Ballerini has held medical, commercial, and management positions with MDxHealth, GenProbe, now part of Hologic, Stryker, Randox Laboratories, and Abbott Laboratories. Peyro Saint-Paul has held corporate leadership positions at Serono, Ipsogen, and Qiagen.

May 26, 2020

Freenome: Bill Quirk, Gary Reedy

Freenome has hired Bill Quirk as its CFO. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler. The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He has had a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson.

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18.

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America.

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.